Analysts Set Natera, Inc. (NASDAQ:NTRA) PT at $184.63

Natera, Inc. (NASDAQ:NTRA) has been given a consensus recommendation of “Buy” by the fifteen analysts that are presently covering the stock, MarketBeat reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $184.63.

NTRA has been the subject of several research reports. Morgan Stanley boosted their price objective on shares of Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research note on Friday, February 28th. Royal Bank Of Canada assumed coverage on Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price target for the company. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, May 15th. Finally, Robert W. Baird upped their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 9,563 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the completion of the sale, the chief executive officer now directly owns 212,541 shares in the company, valued at approximately $29,417,799.81. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the sale, the insider now directly owns 141,782 shares of the company’s stock, valued at approximately $19,917,535.36. This represents a 2.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,755 shares of company stock valued at $8,898,589 in the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NTRA. LRI Investments LLC acquired a new stake in shares of Natera during the fourth quarter worth $29,000. Bank of Jackson Hole Trust purchased a new position in Natera in the 1st quarter worth $29,000. Rakuten Securities Inc. lifted its position in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after acquiring an additional 119 shares during the period. ORG Partners LLC acquired a new position in shares of Natera in the first quarter valued at about $32,000. Finally, TCTC Holdings LLC increased its holdings in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $168.17 on Friday. The stock has a 50 day moving average price of $158.53 and a 200 day moving average price of $158.58. Natera has a 52-week low of $92.14 and a 52-week high of $183.00. The firm has a market capitalization of $22.96 billion, a P/E ratio of -114.40 and a beta of 1.74.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business’s revenue for the quarter was up 36.5% compared to the same quarter last year. During the same period last year, the company earned ($0.56) earnings per share. As a group, sell-side analysts forecast that Natera will post -1.49 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.